| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8680467 | Alzheimer's & Dementia: Translational Research & Clinical Interventions | 2018 | 11 Pages |
Abstract
We describe the first large-scale, potentially label-enabling clinical trial of a preclinical treatment for ADAD. Results from this trial will inform on the efficacy of crenezumab for delaying onset of, slowing decline in, or preventing cognitive impairment in individuals with preclinical ADAD and will foster an improved understanding of AD biomarkers and their relationship to clinical outcomes.
Related Topics
Life Sciences
Neuroscience
Neurology
Authors
Pierre N. Tariot, Francisco Lopera, Jessica B. Langbaum, Ronald G. Thomas, Suzanne Hendrix, Lon S. Schneider, Silvia Rios-Romenets, Margarita Giraldo, Natalia Acosta, Carlos Tobon, Claudia Ramos, Alejandro Espinosa, William Cho, Michael Ward,